title: Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
abstract: Forty-three patients with ovarian cancer were entered on this trial and treated with intravenous (iv) cyclophosphamide (C) and doxorubicin (A), and intraperitoneal (ip) cisplatin (DDP), every 21 days for eight cycles. Following iv hydration, the cisplatin was administered through an intraperitoneal catheter in 2 L of 0.9% normal saline with a 4-h dwell. All patients are evaluable for overall and progression-free survival with a median follow-up of 70 months (range: 3-162 months); 39 patients are evaluable for response. All complete responses were surgically confirmed. The median age was 59 (range 28-82 years); 3 patients were stage IC, 5 were IIC, 14 patients were stage III (optimally debulked), 14 patients were stage III (suboptimally debulked), and 7 patients were stage IV. Two patients had received prior alkylator therapy. Six of 8 patients with Stage IC or II remain without evidence of disease at a mean of 12 years following chemotherapy. Of 14 optimally debulked stage III patients, there were 7 complete responses, 3 partial responses, 1 patient with stable disease, and 3 inevaluable patients. Of 14 suboptimally debulked stage III patients there were 4 complete responses, 4 partial responses, 3 with stable disease, 2 progressions on treatment, and 1 inevaluable patient. Five-year progression-free and overall survivals for stage III optimally debulked patients are 21 and 64%, respectively. At 10 years, progression-free and overall survivals for this group are 21 and 29%, respectively. Toxicity included neutropenia (complicated by sepsis in 2 patients), infrequent thrombocytopenia, and mild anemia. Three patients developed transient serum creatinine elevations >2.0 mg/dl; however, decreased creatinine clearance was noted in 93/258 (36%) of evaluable courses which required a cisplatin dose reduction per protocol. Controllable hypomagnesemia, nausea, and emesis were also observed. We conclude that the combination of iv CA and ip DDP is an effective regimen with long-term progression-free and overall survivals that compare favorably with those of other published studies of intravenous or intraperitoneal chemotherapy. This report is unusual in terms of the prolonged follow-up for all patients enrolled. These long-term results lend further support to recently published trials documenting the efficacy of intraperitoneal chemotherapy for patients with this disease.
authors.affiliation: Department of Gynecologic Oncology, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, California 91010, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Morgan
authors.forename: P
authors.initials: P
authors.lastname: Braly
authors.forename: G
authors.initials: G
authors.lastname: Cecchi
authors.forename: L
authors.initials: L
authors.lastname: Leong
authors.forename: S
authors.initials: S
authors.lastname: Shibata
authors.forename: K
authors.initials: K
authors.lastname: Margolin
authors.forename: G
authors.initials: G
authors.lastname: Somlo
authors.forename: M
authors.initials: M
authors.lastname: McNamara
authors.forename: J
authors.initials: J
authors.lastname: Longmate
authors.forename: S
authors.initials: S
authors.lastname: Schinke
authors.forename: J
authors.initials: J
authors.lastname: Raschko
authors.forename: S
authors.initials: S
authors.lastname: Nagasawa
authors.forename: N
authors.initials: N
authors.lastname: Kogut
authors.forename: P
authors.initials: P
authors.lastname: Parker
authors.forename: A
authors.initials: A
authors.lastname: Stein
authors.forename: J
authors.initials: J
authors.lastname: Cho
authors.forename: E
authors.initials: E
authors.lastname: Smith
authors.forename: P
authors.initials: P
authors.lastname: Coluzzi
authors.forename: L
authors.initials: L
authors.lastname: Najera
authors.forename: D
authors.initials: D
authors.lastname: Johnson
authors.forename: E
authors.initials: E
authors.lastname: Womack
authors.forename: J H
authors.initials: JH
authors.lastname: Doroshow
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007274:Injections, Intraperitoneal; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin